There were 291 patients who received allo-BMT at our hospital between May 2004 and April 2011. Of these, there were 151 patients who received FK-506 and sMTX for prophylaxis of aGVHD. Two patients were excluded from this study because they died before day 11. We retrospectively reviewed the charts for the remaining 149 patients and investigated whether there was a correlation between the omission of day þ 11 MTX and the development of aGVHD. This study was approved by the institutional ethics committee with a waiver of written informed consent because of a retrospective study.
FK-506 was used in cases of either unrelated or HLAmismatched HSCT. FK-506 was administered from day À 1 and the doses were adjusted to maintain blood levels at 10-15 ng/ml. MTX was administered at a dose of 10 mg/m 2 on day 1, and 7 mg/m 2 on days 3, 6 and 11. Patients with lymphoid malignancy were generally conditioned with TBI (12 Gy) and CY (120 mg/kg). In some patients, cytarabine (8 g/m 2 ) was added to this regimen. Most patients with myeloid www.nature.com/bmt malignancy were conditioned with a regimen comprising BU (16 mg/kg orally or 12.8 mg/kg intravenously) and CY (120 mg/kg).
Patients with aplastic anemia were conditioned with TLI (7 Gy) and CY (200 mg/kg). Most patients undergoing the reduced intensity conditioning regimen received fludarabine (125 mg/m 2 ), melphalan (80 mg/m 2 ) and low-dose TBI (2 Gy X 2), or fludarabine (180 mg/m 2 ), BU (6.4 mg/kg intravenously) and low-dose TBI. Continuous baseline characteristics were compared using the Mann-Whitney test. Categorical characteristics were compared using the w 2 test or Fisher's exact test. The incidence of acute GVHD, OS and disease-free survival (DFS) were estimated using the Kaplan-Meier method, and then compared using the log-rank test. All statistical tests were two-sided, with Po0.05 considered statistically significant.
This study analyzed 91 males and 58 females with a median age of 43 years (range: 16-69 years). The median follow-up period was 511 days after BMT (range: 18-2813 days). Most patients received unrelated BMT (n ¼ 147) whereas only two patients received related BMT. No patients received antithymocyte globulin-containing regimen. In this group, there were 22 (14.2%) patients who did not receive day-11 MTX (Table 1) . Patients with (MTX þ group) and without (MTX À group) day-11 MTX did not differ significantly in terms of age, sex, underlying disease, HLA disparity, donor type, donor-recipient sex matching and conditioning regimen. The patients in the MTX À group received multiple courses of HSCT more frequently than the patients in the MTX þ group (Po0.001). In MTX À group, no patients received an alternative immunosuppressant. The reasons for the omission were severe mucositis (n ¼ 13), liver dysfunction including sinusoidal obstruction syndrome (n ¼ 5) or other severe organ dysfunction (n ¼ 4).
The cumulative incidence of acute GVHD did not differ significantly between the MTX þ and MTX À groups in any grade (all grades: 79.1% vs 70.9%, grade II-IV: 44.5% vs 51.9% and grade III and IV: 9.6% vs 18.4%, respectively) (Figure 1a-c) . Although the patients in the MTX À group had lower survival rates for both OS and DFS, these values did not reach statistical significance (Figure 1d and e) In the current study, the impact of the omission of day-11 MTX on the development of aGVHD and survival rates was retrospectively evaluated. In previous reports using CsA and sMTX, the results were somewhat conflicting. Atkinson et al. 4 reported that omission of day-11 MTX was not associated with the incidence of aGVHD in HLA-identical sibling BMT, although the incidence of all-grade GVHD showed borderline significance (P ¼ 0.07). Conversely, Kumar et al. 3 reported that the omission of day-11 MTX was associated with increased risk of severe aGVHD. This discrepancy of results between investigators may be due to patient selection methods and the particular sMTX schedule. In HLA-matched sibling HSCT, the incidence of grade II-IV aGVHD was low (15-25%). 4 On the other hand, the doses of MTX in the report of Kumar et al. were higher (15 mg/m 2 on day 1, 10 mg/m 2 on day 3, 6 and 11) compared with the doses in both Atkinson et al.'s (7.5 mg/m 2 on day 1, 3, 6 and 11) and our reports. Our results showed that the omission of day-11 MTX was not associated with worse incidence and/or severity of aGVHD or with reduced survival rates. The lower dose of MTX might have had no significant effect on the development of aGVDH, or the higherintensity immunosuppressive effect of FK-506 (compared with CsA 5 ) might have overcome the increased risk for acute GVHD by the omission of day-11 MTX. However, the small number of patients is one of the limitations of our study. The incidence of grade III or IV aGVHD was twice higher in MTX À goup. Thus, with more patients, it might have shown a significant difference.
In addition, in view of the retrospective nature of our study, we cannot endorse the safety of omission of day-11 MTX. However, our results imply that day-11 MTX could be aborted if the patient's condition necessitates the discontinuance of sMTX. 
